IP Library › Granted Patent US 12,234,515
Granted Patent B2
US 12,234,515 · App. 16/912,410 · Granted Feb 25, 2025

Enhancement of cancer screening using cell-free viral nucleic acids

Inventors: Yuk-Ming Dennis Lo (Homantin, CN); Rossa Wai Kwun Chiu (Shatin, CN); Kwan Chee Chan (Jordan, CN); Peiyong Jiang (Shatin, CN); Wai Kei Lam (Kowloon, CN)
Assignee: The Chinese University of Hong Kong
C12Q1/6886C12Q1/70C12Q1/705C12Q1/706C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,515
App. No.
16/912,410
Granted
Feb 25, 2025
Kind
B2
Abstract

Cell-free DNA molecules in a mixture of a biological sample can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined. Mixture methylation level(s) can be measured based on one or more amounts of the plurality of cell-free DNA molecules methylated at a set of site(s) of the particular viral genome. The mixture methylation level(s) can be determined in various ways, e.g., as a density of cell-free DNA molecules that are methylated at a site or across multiple sites or regions. The mixture methylation level(s) can be compared to reference methylation level(s), e.g., determined from at least two cohorts of other subjects. The cohorts can have different classifications (including the first condition) associated with the particular viral genome. A first classification of whether the subject has the first condition can be determined based on the comparing.

Claims (61)

1. A system for analyzing a biological sample of a subject that is a human, the biological sample including a mixture of cell-free DNA molecules from a genome of the subject and from one or more other genomes, the system comprising:

a detector configured to measure physical characteristics of a plurality of cell-free DNA molecules in the biological sample and provide data signals corresponding to the physical characteristics, the plurality of cell-free DNA molecules being 1 , 000 or more; and

a logic system comprising one or more processors, memory storing a plurality of instructions, and an interface configured to receive the data signals, wherein the instructions, when executed, perform a method comprising:

analyzing the plurality of cell-free DNA molecules from the biological sample, wherein analyzing a group of the plurality of cell-free DNA molecules includes:

identifying locations of the cell-free DNA molecules in a particular viral genome of a cancer-causing virus; and

determining whether the cell-free DNA molecules are methylated at one or more sites of the particular viral genome;

measuring a mixture methylation level based on amounts of the plurality of cell-free DNA molecules methylated at a set of sites of the particular viral genome based on the locations;

comparing the mixture methylation level to one or more reference methylation levels determined from at least two cohorts of other subjects, wherein the at least two cohorts have different classifications associated with the particular viral genome, the different classifications including a first condition that is a cancer; and

determining a first classification of whether the subject has the first condition based on the comparing, wherein the first condition is nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), cervical cancer (CC), or head and neck squamous cell carcinoma (HNSCC).

2. The system of claim 1 , wherein the different classifications of the at least two cohorts further includes a second condition, wherein the method further comprises:

determining a second classification of whether the subject has the second condition based on the comparing.

3. The system of claim 2 , wherein the one or more reference methylation levels are a plurality of reference methylation levels, wherein the mixture methylation level is compared to the plurality of reference methylation levels that include a first reference methylation level and a second reference methylation level, whether the first reference methylation level is used to determine the first classification of whether the subject has the first condition, and wherein the second reference methylation level is used to determine the second classification of whether the subject has the second condition.

4. The system of claim 3 , wherein the particular viral genome is of Epstein-Barr virus, wherein the first condition is nasopharyngeal cancer, and wherein the second condition is infectious mononucleosis.

5. The system of claim 1 , wherein the first classification is that the subject does not have the first condition.

6. The system of claim 1 , wherein determining the first classification includes determining a level of the first condition.

7. The system of claim 1 , wherein the particular viral genome is of Epstein-Barr virus, and wherein the first condition is nasopharyngeal cancer.

8. The system of claim 1 , wherein measuring the mixture methylation level comprises measuring N mixture methylation levels, N being an integer greater than one, wherein the mixture methylation level is one of the N mixture methylation levels, and wherein the comparing the mixture methylation level to the one or more reference methylation levels comprises comparing the N mixture methylation levels to N reference methylation levels by:

measuring differences between the N mixture methylation levels and N reference methylation levels; and

determining whether the subject belongs to one of the at least two cohorts using the differences.

9. The system of claim 8 , wherein determining whether the subject belongs to one of the at least two cohorts using the differences includes performing a hierarchical clustering analysis.

10. The system of claim 8 , wherein each of the N mixture methylation levels is measured for one of a plurality of predetermined regions.

11. The system of claim 10 , wherein the plurality of predetermined regions are of a same size and span the particular viral genome, and wherein the same size is between 50 bases and 1,000 bases.

12. The system of claim 10 , wherein each of the plurality of predetermined regions satisfies one or more criteria including (1) a difference in a methylation level among multiple subjects of a same cohort and/or (2) a difference in the methylation level between a subject of one cohort and a subject of another cohort.

13. The system of claim 1 , wherein the set of sites reside in a plurality of regions that each satisfies one or more criteria including (1) a difference in a methylation level among multiple subjects of a same cohort and/or (2) a difference in the methylation level between a subject of one cohort and a subject of another cohort.

14. The system of claim 1 , wherein the set of sites satisfies one or more criteria including (1) a difference in a methylation level among multiple subjects of a same cohort and/or (2) a difference in the methylation level between a subject of one cohort and a subject of another cohort.

15. The system of claim 1 , wherein comparing the mixture methylation level to the one or more reference methylation levels determined from the at least two cohorts of other subjects comprises:

inputting the mixture methylation level into a machine learning model that was trained using the one or more reference methylation levels determined from the at least two cohorts of other subjects.

16. The system of claim 1 , wherein the method further comprises:

for each site of the set of sites:

determining a respective number of DNA molecules that are methylated at the site, thereby determining the amounts of the plurality of cell-free DNA molecules methylated at the set of sites of the particular viral genome.

17. The system of claim 16 , wherein the system is configured to perform methylation-aware sequencing of the plurality of cell-free DNA molecules to obtain sequence reads corresponding to the data signals; and wherein the method further comprises:

aligning the sequence reads to the particular viral genome to determine the respective number of DNA molecules that are methylated at each site of the set of sites.

18. The system of claim 1 , wherein the system is configured to perform a methylation-aware assay of the plurality of cell-free DNA molecules as part of determining the locations of the plurality of cell-free DNA molecules and whether the plurality of cell-free DNA molecules are methylated at the set of sites.

19. The system of claim 1 , wherein identifying a location of a cell-free DNA molecule includes determining that the location corresponds to one of the set of sites.

20. The system of claim 1 , wherein the plurality of cell-free DNA molecules are analyzed collectively to determine the amounts of the plurality of cell-free DNA molecules methylated at the set of sites of the particular viral genome.

21. The system of claim 1 , wherein the plurality of cell-free DNA molecules includes at least 10 cell-free DNA molecules located in the particular viral genome.

22. The system of claim 1 , wherein the particular viral genome corresponds to Epstein-Barr virus, human papillomavirus, or hepatitis B virus.

23. The system of claim 1 , wherein the method further comprises:

for each of the plurality of cell-free DNA molecules in a sample:

measuring a size of the cell-free DNA molecule; and

identifying a location of the cell-free DNA molecule in the particular viral genome, the sizes of the plurality of cell-free DNA molecules forming a size distribution, the sample being the biological sample or a different sample including a mixture of cell-free DNA molecules from the genome of the subject and from the one or more other genomes;

determining a statistical value of the size distribution;

comparing the statistical value to a reference size value determined from the at least two cohorts of other subjects;

determining a second classification of whether the subject has the first condition based on the comparing of the statistical value to the reference size value; and

determining a final classification using the first classification and the second classification.

24. The system of claim 1 , wherein the method further comprises:

determining an amount of cell-free DNA molecules derived from the particular viral genome in a sample, the sample being the biological sample or a different sample including a mixture of cell-free DNA molecules from the genome of the subject and from the one or more other genomes;

comparing the amount to a reference value determined from the at least two cohorts of other subjects;

determining a second classification of whether the subject has the first condition based on the comparing of the amount to the reference value; and

determining a final classification using the first classification and the second classification.

25. The system of claim 1 , wherein the system is configured for:

responsive to the first classification being that the subject has the first condition, providing a treatment to the subject to improve the first condition.

26. A computer product for analyzing a biological sample of a subject that is a human, the biological sample including a mixture of cell-free DNA molecules from a genome of the subject and from one or more other genomes, the computer product comprising a non-transitory computer readable medium storing a plurality of instructions that when executed control a computer system to perform:

analyzing a plurality of cell-free DNA molecules from the biological sample, the plurality of cell-free DNA molecules being 1,000 or more, wherein analyzing a group of the plurality of cell-free DNA molecules includes:

identifying locations of the cell-free DNA molecules in a particular viral genome of a cancer-causing virus; and

determining whether the cell-free DNA molecules are methylated at one or more sites of the particular viral genome based on the locations;

measuring a mixture methylation level based on amounts of the plurality of cell-free DNA molecules methylated at a set of sites of the particular viral genome;

comparing the mixture methylation level to one or more reference methylation levels determined from at least two cohorts of other subjects, wherein the at least two cohorts have different classifications associated with the particular viral genome, the different classifications including a first condition, and wherein the first condition is a cancer; and

determining a first classification of whether the subject has the first condition based on the comparing, wherein the first condition is nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), cervical cancer (CC), or head and neck squamous cell carcinoma (HNSCC).

27. The computer product of claim 26 , wherein the set of sites are across a plurality of regions.

28. The system of claim 1 , wherein the mixture methylation level is measured based on the amounts of the plurality of cell-free DNA molecules methylated at the set of sites of the particular viral genome, wherein the set of sites are across a plurality of regions.

Continuity (3)
Continuation 16046795 · Jul 26, 2018
Provisional Application 62537328 · Jul 26, 2017
Related Publication 20200325546A1 · Oct 15, 2020
References Cited (397)
US 7704687B2 · Wang et al. · 2010 [cited by applicant]
US 8620593B2 · Lo et al. · 2013 [cited by applicant]
US 8722334B2 · Lo et al. · 2014 [cited by applicant]
US 8741811B2 · Lo et al. · 2014 [cited by applicant]
US 9121069B2 · Lo et al. · 2015 [cited by applicant]
US 9732390B2 · Lo et al. · 2017 [cited by applicant]
US 9892230B2 · Lo et al. · 2018 [cited by applicant]
US 10095831B2 · Duenwald et al. · 2018 [cited by applicant]
US 10633713B2 · Lo et al. · 2020 [cited by applicant]
US 10731224B2 · Lo · 2020 [cited by examiner]
US 11459616B2 · Namsaraev et al. · 2022 [cited by applicant]
US 11479825B2 · Lo et al. · 2022 [cited by applicant]
US 20030219765A1 · Costa · 2003 [cited by applicant]
US 20050164241A1 · Hahn et al. · 2005 [cited by applicant]
US 20050221314A1 · Berlin et al. · 2005 [cited by applicant]
US 20050282196A1 · Costa · 2005 [cited by applicant]
US 20070122823A1 · Bianchi et al. · 2007 [cited by applicant]
US 20070202525A1 · Quake et al. · 2007 [cited by applicant]
US 20080206749A1 · Lo et al. · 2008 [cited by applicant]
US 20090029377A1 · Lo et al. · 2009 [cited by applicant]
US 20090087847A1 · Lo et al. · 2009 [cited by applicant]
US 20100041048A1 · Diehl et al. · 2010 [cited by applicant]
US 20100136560A1 · Vogelstein et al. · 2010 [cited by applicant]
US 20110171741A1 · Wang et al. · 2011 [cited by applicant]
US 20110276277A1 · Lo et al. · 2011 [cited by applicant]
US 20130017958A1 · Benz et al. · 2013 [cited by applicant]
US 20130040824A1 · Lo et al. · 2013 [cited by applicant]
US 20130237431A1 · Lo et al. · 2013 [cited by applicant]
US 20140080715A1 · Lo et al. · 2014 [cited by applicant]
US 20140100121A1 · Lo et al. · 2014 [cited by applicant]
US 20140178348A1 · Kelsey et al. · 2014 [cited by applicant]
US 20140227699A1 · Lo et al. · 2014 [cited by applicant]
US 20140274740A1 · Srinivasan et al. · 2014 [cited by applicant]
US 20150011403A1 · Lo et al. · 2015 [cited by applicant]
US 20150087529A1 · Lo et al. · 2015 [cited by applicant]
US 20150119260A1 · Chen et al. · 2015 [cited by applicant]
US 20150361505A1 · Song et al. · 2015 [cited by applicant]
US 20150368708A1 · Talasaz · 2015 [cited by applicant]
US 20160002717A1 · Lee et al. · 2016 [cited by applicant]
US 20160017419A1 · Chiu et al. · 2016 [cited by applicant]
US 20160186239A1 · Sinha · 2016 [cited by applicant]
US 20160201142A1 · Lo et al. · 2016 [cited by applicant]
US 20160203260A1 · Lo et al. · 2016 [cited by applicant]
US 20160217251A1 · Lo et al. · 2016 [cited by applicant]
US 20160292356A1 · Kim et al. · 2016 [cited by applicant]
US 20160333416A1 · Babiarz et al. · 2016 [cited by applicant]
US 20170024513A1 · Lo et al. · 2017 [cited by applicant]
US 20170073774A1 · Lo et al. · 2017 [cited by applicant]
US 20170132363A1 · Lo et al. · 2017 [cited by applicant]
US 20170175205A1 · Toung et al. · 2017 [cited by applicant]
US 20170211143A1 · Shendure et al. · 2017 [cited by applicant]
US 20170235877A1 · Lo et al. · 2017 [cited by applicant]
US 20170260590A1 · Eltoukhy et al. · 2017 [cited by applicant]
US 20170321284A1 · McCarroll et al. · 2017 [cited by applicant]
US 20170356053A1 · Otto et al. · 2017 [cited by applicant]
US 20180119230A1 · Velculescu et al. · 2018 [cited by applicant]
CN 1790021 · 2006 [cited by applicant]
CN 101622362 · 2010 [cited by applicant]
CN 102369299 · 2012 [cited by applicant]
CN 104662168 · 2015 [cited by applicant]
CN 104781421 · 2015 [cited by applicant]
CN 104781422 · 2015 [cited by applicant]
CN 105296606A · 2016 [cited by applicant]
CN 105874068 · 2016 [cited by applicant]
CN 106795562 · 2017 [cited by applicant]
CN 108026572A · 2018 [cited by applicant]
CN 110100013A · 2019 [cited by applicant]
EA 005140 · 2004 [cited by applicant]
EA 010571 · 2008 [cited by applicant]
EA 011608 · 2009 [cited by applicant]
EA 018444 · 2013 [cited by applicant]
EP 2426217 · 2012 [cited by applicant]
EP 2864501 · 2015 [cited by applicant]
GB 2485635 · 2012 [cited by applicant]
JP 2005514956 · 2005 [cited by applicant]
JP 2010534068 · 2010 [cited by applicant]
JP 2010534069 · 2010 [cited by applicant]
JP 2014534507 · 2014 [cited by applicant]
JP 2015536639A · 2015 [cited by applicant]
KR 20150082228A · 2015 [cited by applicant]
WO 0061612 · 2000 [cited by applicant]
WO 03062441 · 2003 [cited by applicant]
WO 2004078999 · 2004 [cited by applicant]
WO 2004111272 · 2004 [cited by applicant]
WO 2007028155 · 2007 [cited by applicant]
WO 2007100911 · 2007 [cited by applicant]
WO 2008024009 · 2008 [cited by applicant]
WO 2008104122 · 2008 [cited by applicant]
WO 2008146309 · 2008 [cited by applicant]
WO 2009013492 · 2009 [cited by applicant]
WO 2009013496 · 2009 [cited by applicant]
WO 2009019455 · 2009 [cited by applicant]
WO 2010112316 · 2010 [cited by applicant]
WO 2011038507 · 2011 [cited by applicant]
WO 2011053790 · 2011 [cited by applicant]
WO 2011054936 · 2011 [cited by applicant]
WO 2011057094 · 2011 [cited by applicant]
WO 2011073665 · 2011 [cited by applicant]
WO 2011090557 · 2011 [cited by applicant]
WO 2011091046 · 2011 [cited by applicant]
WO 2011103236 · 2011 [cited by applicant]
WO 2011130751 · 2011 [cited by applicant]
WO 2012071621 · 2012 [cited by applicant]
WO 2012103031 · 2012 [cited by applicant]
WO 2013045432 · 2013 [cited by applicant]
WO 2013052913 · 2013 [cited by applicant]
WO 2013060762 · 2013 [cited by applicant]
WO 2013066641 · 2013 [cited by applicant]
WO 2013086352 · 2013 [cited by applicant]
WO 2013132305 · 2013 [cited by applicant]
WO 2013138510 · 2013 [cited by applicant]
WO 2013190441 · 2013 [cited by applicant]
WO 2014004726 · 2014 [cited by applicant]
WO 2014039556 · 2014 [cited by applicant]
WO 2014043763 · 2014 [cited by applicant]
WO WO2014043763A1 · 2014 [cited by examiner]
WO 2014130890 · 2014 [cited by applicant]
WO 2015169947 · 2015 [cited by applicant]
WO 2015159292 · 2015 [cited by applicant]
WO 2016008451 · 2016 [cited by applicant]
WO 2016015058 · 2016 [cited by applicant]
WO 2016054255 · 2016 [cited by applicant]
WO 2016094853 · 2016 [cited by applicant]
WO 2016112850 · 2016 [cited by applicant]
WO 2016116033 · 2016 [cited by applicant]
WO 2016127944 · 2016 [cited by applicant]
WO 2017012544 · 2017 [cited by applicant]
WO 2017012592 · 2017 [cited by applicant]
WO 2017019751 · 2017 [cited by applicant]
WO 2017105353 · 2017 [cited by applicant]
WO 2017206888 · 2017 [cited by applicant]
WO 2018081130 · 2018 [cited by applicant]
WO 2018137685 · 2018 [cited by applicant]
Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res. Apr. 1, 2004;10(7):2401-6. (Year: 2004). [cited by examiner]
Nawaz et al. Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. Clin Epigenetics. Aug. 22, 2015;7(1):89. doi: 10.1186/s13148-015-0119-8. PMID: (Ye… [cited by examiner]
U.S. Appl. No. 15/793,830, Non-Final Office Action mailed on May 28, 2021, 14 pages. [cited by applicant]
U.S. Appl. No. 15/793,830, Non-Final Office Action mailed on Feb. 17, 2021, 20 pages. [cited by applicant]
Accomando et al., Quantitative Reconstruction of Leukocyte Subsets Using DNA Methylation, Genome Biology, vol. 15, No. R50, 2014, 12 pages. [cited by applicant]
Alexandrov et al., Signatures of Mutational Processes in Human Cancer, Nature, vol. 500, No. 7463, Aug. 22, 2013, 24 pages. [cited by applicant]
Batzer et al., Enhanced Evolutionary PCR Using Oligonucleotides with Inosine at the 3′-Terminus, Nucleic Acids Research, vol. 19, No. 18, Sep. 25, 1991, p. 5081. [cited by applicant]
Benjamini et al., Controlling the False Discovery Rate—A Practical and Powerful Approach to Multiple Testing, Journal of the Royal Statistical Society Series B-Statistical Methodology, vol. 57, No. 1, Nov. 1995, pp. 289… [cited by applicant]
Bettegowda et al., Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, Science Translational Medicine, vol. 6, No. 224, Feb. 19, 2014, 25 pages. [cited by applicant]
Boyle et al., High-Resolution Mapping and Characterization of Open Chromatin Across the Genome, Cell, vol. 132, No. 2, Jan. 25, 2008, pp. 311-322. [cited by applicant]
Buenrostro et al., Transposition of Native Chromatin for Fast and Sensitive Epigenomic Profiling of Open Chromatin, DNA-Binding Proteins and Nucleosome Position, Nature Methods, vol. 10, No. 12, Dec. 2013, pp. 1213-1218. [cited by applicant]
Chan et al., Plasma DNA Aberrations in Systemic Lupus Erythematosus Revealed by Genomic and Methylomic Sequencing, Proceedings of the National Academy of Sciences, vol. 111, No. 49, Nov. 26, 2014, pp. E5302-E5311. [cited by applicant]
Chan et al., Second Generation Noninvasive Fetal Genome Analysis Reveals De Novo Mutations, Single-Base Parental Inheritance, and Preferred DNA Ends, Proceedings of the National Academy of Sciences of the United States … [cited by applicant]
Chim et al., Detection of the Placental Epigenetic Signature of the Maspin Gene in Material Plasma, XP-002355638, Proceedings of the National Academy of Sciences of the United States of America, vol. 102, No. 41, Oct. 1… [cited by applicant]
De Mattos-Arruda et al., Cerebrospinal Fluid-Derived Circulating Tumour DNA Better Represents the Genomic Alterations of Brain Tumours than Plasma, Nature Communications, vol. 6, Nov. 10, 2015, 6 pages. [cited by applicant]
De Vlaminck et al., Noninvasive Monitoring of Infection and Rejection After Lung Transplantation, Proceedings of the National Academy of Sciences, vol. 112, No. 43, Oct. 27, 2015, pp. 13336-133341. [cited by applicant]
Dear, One by One: Single Molecule Tools for Genomics, Briefings in Functional Genomics and Proteomics, vol. 1, No. 4, Jan. 2003, pp. 397-416. [cited by applicant]
Dressman et al., Transforming Single DNA Molecules into Fluorescent Magnetic Particles for Detection and Enumeration of Genetic Variations, Proceedings of the National Academy of Sciences of the United States of America… [cited by applicant]
European Application No. 18838558.7, Office Action mailed on Mar. 7, 2022, 7 pages. [cited by applicant]
Fernandez et al., A DNA Methylation Fingerprint of 1628 Human Samples, Genome Research, vol. 22, No. 2, Feb. 2012, pp. 407-419. [cited by applicant]
Giresi et al., FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) Isolates Active Regulatory Elements from Human Chromatin, Genome Research, vol. 17, No. 6, Jun. 2007, pp. 877-885. [cited by applicant]
Harris et al., Single-Molecule DNA Sequencing of a Viral Genome, Science, vol. 320, No. 5872, Apr. 4, 2008, pp. 106-109. [cited by applicant]
Houseman et al., Cell-Composition Effects in the Analysis of DNA Methylation Array Data: A Mathematical Perspective, BMC Bioinformatics, vol. 16, No. 95, 2015, 16 pages. [cited by applicant]
Houseman et al., DNA Methylation Arrays as Surrogate Measures of Cell Mixture Distribution, BMC Bioinformatics, vol. 13, No. 86, May 8, 2012, pp. 1-16. [cited by applicant]
Houseman et al., Reference-Free Cell Mixture Adjustments in Analysis of DNA Methylation Data, Bioinformatics, Genetics and Population Analysis, vol. 30, No. 10, May 15, 2014, pp. 1431-1439. [cited by applicant]
Korbel et al., Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome, Science, vol. 318, No. 5849, Oct. 19, 2007, pp. 420-426. [cited by applicant]
Li et al., A Survey of Sequence Alignment Algorithms for Next-generation Sequencing, Briefings in Bioinformatics, vol. 11, No. 5, May 11, 2010, pp. 473-483. [cited by applicant]
Li et al., SOAP2: An Improved Ultrafast Tool for Short Read Alignment, Bioinformatics, vol. 25, No. 15, Aug. 1, 2009, pp. 1966-1967. [cited by applicant]
Lian et al., Loss of 5-Hydroxymethylcytosine as an Epigenetic Hallmark of Melanoma, Cell, vol. 150, Issue 6, Sep. 14, 2012, pp. 1135-1146. [cited by applicant]
Liu et al., Decoding Circulating Nucleic Acids in Human Serum Using Microfluidic Single Molecule Spectroscopy, Journal of the American Chemical Society, vol. 132, No. 16, Apr. 5, 2010, pp. 5793-5798. [cited by applicant]
Margulies et al., Genome Sequencing in Microfabricated High-Density Picolitre Reactors, Nature, vol. 437, No. 7057, Sep. 15, 2005, pp. 376-380. [cited by applicant]
Mazurek et al., Assessment of the Total cfDNA and HPV16/18 Detection in Plasma Samples of Head and Neck Squamous Cell Carcinoma Patients, Oral Oncology, vol. 54, Jan. 11, 2016, pp. 36-41. [cited by applicant]
Norton et al., Cell-Free DNA Analysis for Noninvasive Examination of Trisomy, The New England Journal of Medicine, vol. 372, No. 17, Apr. 23, 2015, pp. 1589-1597. [cited by applicant]
Nygren et al., Quantification of Fetal DNA by Use of Methylation-Based DNA Discrimination, Clinical Chemistry, vol. 56, No. 10, Available Online at: http://www.clinchem.org/content/supp1/2010/07/28/clinchem.2010.146290.… [cited by applicant]
Ohtsuka et al., An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Deoxyinosine at Ambiguous Codon Positions, Journal of Biological Chemistry, vol. 260, No. 5, Mar. 10, 1985, pp. 26… [cited by applicant]
Rossolini et al., Use of Deoxyinosine-Containing Primers Vs Degenerate Primers for Polymerase Chain Reaction Based on Ambiguous Sequence Information, Molecular and Cellular Probes, vol. 8, No. 2, Apr. 1994, pp. 91-98. [cited by applicant]
Singapore Application No. 11201903509Q, Written Opinion mailed on Dec. 21, 2021, 7 pages. [cited by applicant]
Shendure et al., Next-Generation DNA Sequencing, Nature Biotechnology, vol. 26, No. 10, Oct. 1, 2008, pp. 1135-1145. [cited by applicant]
Snyder et al., Cell-Free DNA Comprises an In Vivo Nucleosome Footprint That Informs Its Tissues-Of-Origin, Cell, vol. 167, Jan. 2016, pp. 57-68. [cited by applicant]
Soni et al., Progress Toward Ultrafast DNA Sequencing Using Solid-State Nanopores, Clinical Chemistry, vol. 53, No. 11, Nov. 1, 2007, pp. 1996-2001. [cited by applicant]
Taiwan Application No. 106136597, Office Action mailed on Nov. 25, 2021, 6 pages (5 pages of Original Document and 1 pages of English Translation). [cited by applicant]
U.S. Appl. No. 13/789,553, Final Office Action mailed on May 5, 2017, 16 pages. [cited by applicant]
U.S. Appl. No. 13/789,553, Non-Final Office Action mailed on Feb. 12, 2016, 18 pages. [cited by applicant]
U.S. Appl. No. 13/789,553, Non-Final Office Action mailed on Oct. 13, 2016, 20 pages. [cited by applicant]
U.S. Appl. No. 13/789,553, Notice of Allowance mailed on Oct. 5, 2017, 8 pages. [cited by applicant]
U.S. Appl. No. 14/089,720, Non-Final Office Action mailed on Aug. 23, 2016, 15 pages. [cited by applicant]
U.S. Appl. No. 15/880,403, Diagnostic Applications Using Nucleic Acid Fragments filed Jan. 25, 2018, 201 pages. [cited by applicant]
U.S. Appl. No. 60/951,438, Determining a Nucleic Acid Sequence Imbalance filed Jul. 23, 2007, 90 pages. [cited by applicant]
U.S. Appl. No. 62/580,906, Using Nucleic Acid Size Range for Noninvasive Prenatal Testing and Cancer Detection filed Nov. 2, 2017, 89 pages. [cited by applicant]
Allday et al., CpG Methylation of Viral DNA in EBV-Associated Tumours, International Journal of Cancer, vol. 45, 1990, pp. 1125-1130. [cited by applicant]
Australian Application No. 2013229186, First Examination Report mailed on Dec. 1, 2015, 5 pages. [cited by applicant]
Camargo et al., Validation and Calibration of Next-Generation Sequencing to Identify Epstein-Barr Virus-Positive Gastric Cancer in the Cancer Genome Atlas, Gastric Cancer, vol. 19, No. 2, Apr. 2016, pp. 676-681. [cited by applicant]
Chan et al., Effects of Preanalytical Factors on the Molecular Size of Cell-free DNA in Blood, Clinical Chemistry, vol. 51, No. 4, Apr. 2005, pp. 781-784. [cited by applicant]
Chan et al., Persistent Aberrations in Circulating DNA Integrity after Radiotherapy are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients, Imaging, Diagnosis, Prognosis, Clinical Cancer Research, vol. … [cited by applicant]
Chen et al., Quantification of 5-Methylcytosine and 5-Hydroxymethylcytosine in Genomic DNA from Hepatocellular Carcinoma Tissues by Capillary Hydrophilic-Interaction Liquid Chromatography/Quadrupole TOF Mass Spectometry… [cited by applicant]
Cook et al., Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction, Circulation, vol. 11, No. 5, Feb. 20, 2007, pp. 928-935. [cited by applicant]
Devonshire et al., Towards Standardisation of Cell-Free DNA Measurement in Plasma: Controls for Extraction Efficiency, Fragment Size Bias and Quantification, Analytical and Bioanalytical Chemistry, vol. 406, No. 26, Oct… [cited by applicant]
European Application No. 13757943.9, Extended European Search Report mailed on Sep. 7, 2015, 7 pages. [cited by applicant]
European Application No. 14193706.0, Extended European Search Report mailed on Mar. 18, 2015, 7 pages. [cited by applicant]
European Application No. 14193706.0, Office Action mailed on Nov. 3, 2015, 4 pages. [cited by applicant]
Fernandez et al., The Dynamic DNA Methylomes of Double-Stranded DNA Viruses Associated with Human Cancer, Genome Research, Cold Spring Harbor Laboratory Press, vol. 19, No. 3, Mar. 1, 2009, pp. 438-451. [cited by applicant]
Hsiao et al., Detection of Cell Free Epstein-Barr Virus DNA in Sera from Patients with Nasapharyngeal Carcinoma, Cancer, vol. 94, No. 3, Feb. 1, 2002, pp. 723-729. [cited by applicant]
Jiang et al., Lengthening and Shortening of Plasma DNA in Hepatocellular Carcinoma Patients, Proceedings of the National Academy of Sciences, vol. 112, No. 11, Feb. 2, 2015, pp. E1317-E1325. [cited by applicant]
Jo et al., A Single-Molecule Barcoding System using Nanoslits for DNA Analysis, PNAS, vol. 104, No. 8, Feb. 20, 2007, pp. 2673-2678. [cited by applicant]
Japanese Application No. 2014-560451, Office Action mailed on Feb. 23, 2016, 10 pages (3 pages of Original Document and 7 pages of English Translation). [cited by applicant]
Japanese Application No. 2017-000134, Office Action mailed on Dec. 12, 2017, 6 pages (2 pages of Original Document and 4 pages of English Translation). [cited by applicant]
Kanakry et al., Characterizing the CpG Methylation of Epstein-Barr Virus DNA in the Plasma of Patients with Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma, Blood, vol. 122, No. 21, Nov. 15, 2013, pp. 1-3. [cited by applicant]
Koh et al., Noninvasive in Vivo Monitoring of Tissue-Specific Global Gene Expression in Humans, Proceedings of the National Academy of Sciences of the United States of America, vol. 111, No. 20, May 20, 2014, pp. 7361-7… [cited by applicant]
Kwok et al., Genomic Sequencing and Comparative Analysis of Epstein-Barr Virus Genome Isolated from Primary Nasopharyngeal Carcinoma Biopsy, PLoS One, vol. 7, No. 5, May 2012, pp. 1-10. [cited by applicant]
Lam et al., Sequencing-based Counting and Size Profiling of Plasma Epstein-Barr Virus DNA Enhance Population Screening of Nasopharyngeal Carcinoma, Proceedings of the National Academy of Sciences of the United States of… [cited by applicant]
Lawrence et al., Mutational Heterogeneity in Cancer and the Search for New Cancer Genes, Nature, vol. 499, No. 7457, Jul. 11, 2013, pp. 214-218. [cited by applicant]
Liu et al., The Diagnostic Accuracy of Pleural Effusion and Plasma Samples Versus Tumour Tissue for Detection of EGFR Mutation in Patients with Advanced Non-small Cell Lung Cancer: Comparison of Methodologies, Journal o… [cited by applicant]
Lo et al., Molecular Prognostication of Nasopharyngeal Carcinoma by Quantitative Analysis of Circulating Epstein-Barr Virus DNA, Cancer Research, vol. 60, No. 24, Dec. 15, 2000, pp. 6878-6881. [cited by applicant]
Lo et al., Quantitative and Temporal Correlation between Circulating Cell-Free Epstein-Barr Virus DNA and Tumor Recurrence in Nasopharyngeal Carcinoma, Cancer Research, vol. 59, Nov. 1, 1999, pp. 5452-5455. [cited by applicant]
Manokhina et al., Quantification of Cell-free DNA in Normal and Complicated Pregnancies: Overcoming Biological and Technical Issues, PLoS One, vol. 9, No. 7, Jul. 2, 2014, pp. 1-7. [cited by applicant]
O'Marcaigh et al., Estimating the Predictive Value of a Diagnostic Test, Clinical Pediatrics, vol. 32, No. 8, Aug. 1993, pp. 485-491. [cited by applicant]
International Application No. PCT/CN2016/070785, International Search Report and Written Opinion mailed on Apr. 22, 2016, 7 pages. [cited by applicant]
International Application No. PCT/CN2018/097072, International Search Report and Written Opinion mailed on Nov. 5, 2018, 10 pages. [cited by applicant]
International Application No. PCT/US2017/046582, International Search Report and Written Opinion mailed on Nov. 20, 2017, 12 pages. [cited by applicant]
Pepe et al., Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker, American Journal of Epidemiology, vol. 159, No. 9, May 1, 2004, pp. 882-890. [cited by applicant]
Robin et al., Comparison of DNA Quantification Methods for Next Generation Sequencing, Scientific Reports, vol. 6, No. 1, Article No. 24067, Apr. 2016, pp. 1-10. [cited by applicant]
Santpere et al., Genome-Wide Analysis of Wild-Type Epstein-Barr Virus Genomes Derived from Healthy Individuals of the 1000 Genomes Project, Genome Biology, vol. 6, No. 4, Apr. 2014, pp. 846-860. [cited by applicant]
Stebbing et al., Cell-Free DNA as a Biomarker in the Context of Cancer, Viruses, and Methylation, The Journal of Infectious Diseases, vol. 25, No. 7, Apr. 1, 2012, pp. 1032-1034. [cited by applicant]
Tanic et al., Epigenome-Wide Association Studies for Cancer Biomarker Discovery in Circulating Cell-Free DNA: Technical Advances and Challenges, Current Opinion in Genetics & Development, vol. 42, Feb. 16, 2017, pp. 48-… [cited by applicant]
Tierney et al., Epstein-Barr Virus BamHI W Repeat Number Limits EBNA2/EBNA-LP Coexpression in newly Infected B Cells and the Efficiency of B-Cell Transformation: a Rationale for the Multiple W Repeats in Wild-Type Virus… [cited by applicant]
Togneri et al., Genomic Complexity of Urothelial Bladder Cancer Revealed in Urinary cfDNA, European Journal of Human Genetics, vol. 24, No. 8, Aug. 2016, pp. 1167-1174. [cited by applicant]
Tsuchiya, Diagnosis of Epstein-Barr Virus Associated Diseases, Critical Reviews in Oncology/Hematology, vol. 44, No. 3, Dec. 2002, pp. 227-238. [cited by applicant]
Umetani et al., Increased Integrity of Free Circulating DNA in Sera Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats, Clinical Chemistry, vol. 52, Issue 6, 2006, pp. 1062-1069. [cited by applicant]
Wei et al., Current Management Strategy of Nasopharyngeal Carcinoma, Clinical and Experimental Otorhinolaryngology, vol. 3, No. 1, Mar. 2010, pp. 1-12. [cited by applicant]
Xia et al., Accurate Genome Relative Abundance Estimation Based on Shotgun Metagenomic Reads, PLOS ONE, vol. 6, No. 12, Dec. 6, 2011, pp. 1-12. [cited by applicant]
Zhao et al., Genome-Wide Methylation Profiling of the Different Stages of Hepatitis B Virus-Related Hepatocellular Carcinoma Development in Plasma Cell-Free DNA Reveals Potential Biomarkers for Early Detection and High-… [cited by applicant]
TruSeq DNA PCR-Free Sample Preparation Kit, Illumina, Data Sheet: Sequencing, Available online at: http://www.illumina.com/contenUdam/illuminamarketing/documents/products/datasheets/datasheet_truseq_dna_pcr_free_sample_… [cited by applicant]
U.S. Appl. No. 13/801,748, Non-Final Office Action, mailed on Aug. 11, 2017, 18 pages. [cited by applicant]
U.S. Appl. No. 15/362,631, Non-Final Office Action, mailed on Jan. 11, 2018, 7 pages. [cited by applicant]
Aird et al., Analyzing and Minimizing PCR Amplification Bias in Illumina Sequencing Libraries, Genome Biology, vol. 12, No. R18, Available online at: http://genomebiology.com/2011/12/2/R18, Feb. 2011, pp. 1-14. [cited by applicant]
Australia Application No. 2013278994, First Examination Report, mailed on Aug. 17, 2016, 3 pages. [cited by applicant]
Australia Application No. 2013278994, Notice of Acceptance, mailed on Mar. 23, 2017, 3 pages. [cited by applicant]
Balakrishnan et al., Epigenetic Regulation of Viral Biological Processes, Viruses, vol. 9, No. 11, 2017, pp. 1-14. [cited by applicant]
Beck et al., Next Generation Sequencing of Serum Circulating Nucleic Acids from Patients with Invasive Ductal Breast Cancer Reveals Differences to Healthy and Nonmalignant Controls, Molecular Cancer Research, vol. 8, No… [cited by applicant]
Beck et al., Profile of the Circulating DNA in Apparently Healthy Individuals, Clinical Chemistry, vol. 55, No. 4, Apr. 2009, pp. 730-738. [cited by applicant]
Bianchi et al., Large Amounts of Cell-Free Fetal DNA are Present in Amniotic Fluid, Clinical Chemistry, vol. 47, No. 10, Oct. 2001, pp. 1867-1869. [cited by applicant]
Canada Application No. 2,876,327, Office Action, mailed on Jul. 7, 2017, 4 pages. [cited by applicant]
Chan et al., Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer, The New England Journal of Medicine, vol. 377, No. 6, Aug. 10, 2017, 16 pages. [cited by applicant]
Chan et al., Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencina, Clinical Chemistry, vol. 59, … [cited by applicant]
Chan et al., Early Detection of Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA Analysis in a Surveillance Program, Cancer, vol. 119, No. 10, May 15, 2013, pp. 1838-1844. [cited by applicant]
Chan et al., Molecular Characterization of Circulating EBV DNA in the Plasma of Nasopharyngeal Carcinoma and Lymphoma Patients, Cancer Research, vol. 63, No. 9, May 1, 2003, pp. 2028-2032. [cited by applicant]
Chan et al., Noninvasive Detection of Cancer-Associated Genome-Wide Hypomethylation and Copy Number Aberrations by Plasma DNA Bisulfite Sequencing, Proceedings of the National Academy of Sciences, vol. 110, No. 47, Nov.… [cited by applicant]
Chan et al., Plasma Epstein-Barr Virus DNA as a Biomarker for Nasopharyngeal Carcinoma, Chinese Journal of Cancer, vol. 33, No. 12, Dec. 2014, pp. 598-603. [cited by applicant]
Chan et al., Size Distributions of Maternal and Fetal DNA in Maternal Plasma, Clinical Chemistry, vol. 50, No. 1, Jan. 2004, pp. 88-92. [cited by applicant]
Chandrananda et al., High-Resolution Characterization of Sequence Signatures due to Non-Random Cleavage of Cell-Free DNA, BMC Medical Genomics, vol. 8, No. 29, Jun. 17, 2015, pp. 1-19. [cited by applicant]
Chang et al., Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer, Journal of the National Cancer Institute, vol. 94, No. 22, Nov. 20, 2002, pp. 1697-1703. [cited by applicant]
Chiu et al., Non-Invasive Prenatal Diagnosis by Single Molecule Counting Technologies, Trends in Genetics, vol. 25, No. 7, Jun. 18, 2009, pp. 324-331. [cited by applicant]
Chiu et al., Noninvasive Prenatal Diagnosis of Fetal Chromosomal Aneuploidy by Massively Parallel Genomic Sequencing of DNA in Maternal Plasma, Proceedings of the National Academy of Sciences, vol. 105, No. 51, Dec. 23,… [cited by applicant]
Cibulskis et al., Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples, Nature Biotechnology, vol. 31, No. 3, Mar. 2013, pp. 213-219. [cited by applicant]
Daniels et al., Whole Genome Sequencing for Lung Cancer, Journal of Thoracic Disease, vol. 4, No. 2, Apr. 1, 2012, pp. 155-163. [cited by applicant]
Diaz Jr. et al., The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers, Nature, vol. 486, No. 7404, Jun. 28, 2012, 10 pages. [cited by applicant]
Diaz Jr. et al., Supplementary Information: The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers, Nature, vol. 486, No. 7404, Jun. 28, 2012, 25 pages. [cited by applicant]
Diehl et al., Circulating Mutant DNA to Assess Tumor Dynamics, Nature Medicine, vol. 14, No. 9, Sep. 2008, pp. 985-990. [cited by applicant]
Diehl et al., Detection and Quantification of Mutations in the Plasma of Patients with Colorectal Tumors, Proceedings of the National Academy of Sciences, vol. 102, No. 45, Nov. 8, 2005, pp. 16368-16373. [cited by applicant]
Ding et al., MS Analysis of Single-Nucleotide Differences in Circulating Nucleic Acids: Application to Noninvasive Prenatal Diagnosis, Proceedings of the National Academy of Sciences of the United States (PNAS), Nationa… [cited by applicant]
Eurasian Application No. 201500027, Office Action, mailed on Mar. 10, 2017, 19 pages (11 pages of Original Document and 8 pages of English Translation). [cited by applicant]
Eurasian Application No. 201500027, Office Action, mailed on Dec. 19, 2017, 21 pages (16 pages of Original Document and 21 pages of English Translation). [cited by applicant]
Ellinger et al., Cell-Free Circulating DNA: Diagnostic Value in Patients with Testicular Germ Cell Cancer, The Journal of Urology, vol. 181, No. 1, Jan. 2009, pp. 363-371. [cited by applicant]
European Application No. 13807105.5, Extended European Search Report, mailed on Feb. 15, 2016, 9 pages. [cited by applicant]
European Application No. 13807105.5, Office Action, mailed on Feb. 27, 2017, 10 pages. [cited by applicant]
Fan et al., Analysis of the Size Distributions of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing, Clinical Chemistry, vol. 56, No. 8, Aug. 2010, pp. 1279-1286. [cited by applicant]
Fan et al., Detection of Aneuploidy with Digital Polymerase Chain Reaction, Analytical Chemistry, American Chemical Society, vol. 79, No. 19, Oct. 1, 2007, pp. 7576-7579. [cited by applicant]
Fan et al., Noninvasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA from Maternal Blood, Proceedings National Academy of Sciences, vol. 105, No. 42, Oct. 21, 2008, pp. 16266-16271. [cited by applicant]
Fan et al., Whole-Genome Molecular Haplotyping of Single Cells, Nature Biotechnology, vol. 29, No. 1, Jan. 2011, pp. 51-57. [cited by applicant]
Forshew et al., Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA, Science Translational Medicine, American Association for the Advancement of Science, vol. 4, No. 1… [cited by applicant]
Gerlinger et al., Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing, The New England Journal of Medicine, vol. 366, No. 10, Available online at: www.nejm.org, Mar. 8, 2012, pp. 883-892. [cited by applicant]
Goode et al., A Simple Consensus Approach Improves Somatic Mutation Prediction Accuracy, Genome Medicine, vol. 5, No. 90, 2013, pp. 1-14. [cited by applicant]
Hanlon et al., Evaluation of 13q14 Status in Multiple Myeloma by Digital Single Nucleotide Polymorphism Technology, Journal of Molecular Diagnostics, vol. 11, No. 5, Sep. 2009, pp. 450-457. [cited by applicant]
Heidary et al., The Dynamic Range of Circulating Tumor DNA in Metastatic Breast Cancer, Breast Cancer Research, vol. 16, No. 421, Aug. 9, 2014, pp. 1-10. [cited by applicant]
Hongkong Application No. 18101202.2, Search Report, mailed on Feb. 6, 2018, 3 pages. [cited by applicant]
Hohaus et al., The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma, Clinical Cancer Research, vol. 17, No. 9, May 1, 2011, pp. 2885… [cited by applicant]
Hou et al., Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm, Cell, vol. 148, No. 5, Mar. 2, 2012, pp. 873-885. [cited by applicant]
Israel Application No. 235967, Office Action, mailed on Aug. 14, 2017, 2 pages. [cited by applicant]
Ivanov et al., Non-Random Fragmentation Patterns in Circulating Cell-Free DNA Reflect Epigenetic Regulation, BMC Genomics, vol. 16, Dec. 16, 2015, 12 pages. [cited by applicant]
Jacobs et al., Detectable Clonal Mosaicism and its Relationship to Aging and Cancer, Nature Genetics, vol. 44, No. 6, May 6, 2012, 20 pages. [cited by applicant]
Jahr et al., DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for their Origin from Apoptotic and Necrotic Cells, Cancer Research, vol. 61, No. 4, Feb. 15, 2001, pp. 1659-1665. [cited by applicant]
Jiang et al., Increased Plasma DNA Integrity Index in Head and Neck Cancer Patients, International Journal of Cancer, vol. 119, No. 11, Dec. 1, 2006, pp. 2673-2676. [cited by applicant]
Japan Application No. 2015-517896, Office Action, mailed on Jul. 26, 2016, 18 pages (7 pages of Original Document and 11 pages of English Translation). [cited by applicant]
Japan Application No. 2015-517896, Office Action, mailed on Feb. 6, 2018, 7 pages (3 pages of Original Document and 4 pages of English Translation). [cited by applicant]
Japan Application No. 2015-517896, Office Action, mailed on Jun. 6, 2017, 7 pages (3 pages of Original Document and 4 pages of English Translation). [cited by applicant]
Jung et al., Cell-Free DNA in the Blood as a Solid Tumor Biomarker—A Critical Appraisal of the Literature, Clinica Chimica Acta, vol. 411, No. 21-22, Nov. 11, 2010, pp. 1611-1624. [cited by applicant]
Karlsson et al., Amplification-Free Sequencing of Cell-Free DNA for Prenatal Non-Invasive Diagnosis of Chromosomal Aberrations, Genomics, vol. 105, No. 3, Mar. 2015, pp. 150-158. [cited by applicant]
Kinde et al., Detection and Quantification of Rare Mutations with Massively Parallel Sequencing, Proceedings of the National Academy of Sciences, vol. 108, No. 23, Jun. 7, 2011, pp. 9530-9535. [cited by applicant]
Kitzman et al., Noninvasive Whole-Genome Sequencing of a Human Fetus, Science Translation Medicine, vol. 4, Nos. 137-140, Jun. 2012, 11 pages. [cited by applicant]
Kozarewa et al., Amplification-Free Illumina Sequencing-Library Preparation Facilitates Improved Mapping and Assembly of (GC)-Biased Genomes, Nature Methods, vol. 6, No. 4, Apr. 2009, pp. 291-295. [cited by applicant]
Korea Application No. 10-2015-7001225, Office Action, mailed on Oct. 25, 2016, 16 pages (8 pages of Original Document and 8 pages of English Translation). [cited by applicant]
Laframboise et al., Allele-Specific Amplification in Cancer Revealed by SNP Array Analysis, PLoS Computational Biology, vol. 1, No. 6, Nov. 2005, pp. 0507-0517. [cited by applicant]
Lam et al., Sequencing-Based Counting and Size Profiling of Plasma Epstein-Barr Virus DNA Enhance Population Screening of Nasopharyngeal Carincinoma, Science Translational Medicine Submitted Manuscript; Template Updated… [cited by applicant]
Lapaire et al., Array-CGH Analysis of Cell-Free Fetal DNA in 10 mL of Amniotic Fluid Supernatant, Prenatal Diagnosis, vol. 27, No. 7, Jul. 2007, pp. 616-621. [cited by applicant]
Lapaire et al., Cell-Free Fetal DNA in Amniotic Fluid: Unique Fragmentation Signatures in Euploid and Aneuploid Fetuses, Clinical Chemistry, vol. 53, No. 3, Mar. 2007, pp. 405-411. [cited by applicant]
Lapaire et al., Larger Columns and Change of Lysis Buffer Increase the Yield of Cell-Free DNA Extracted from Amniotic Fluid, Clinical Chemistry, vol. 52, No. 1, Jan. 2006, pp. 156-157. [cited by applicant]
Larkin et al., A Phase II Trial of Nilotinib in the Treatment of Patients with KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM), Online Conference Poster, Institute of Cancer Research, Available Online at: https:… [cited by applicant]
Larrabee et al., Microarray Analysis of Cell-Free Fetal DNA in Amniotic Fluid: A Prenatal Molecular Karyotype, The American Society of Human Genetics, vol. 75, No. 3, Sep. 1, 2004, pp. 485-491. [cited by applicant]
Leary et al., Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing, Science Translational Medicine, vol. 4, No. 162, Nov. 28, 2012, pp. 1-21. [cited by applicant]
Leary et al., Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing, Science Translational Medicine, vol. 2, No. 20, Available Online at: www.ScienceTranslationaiMedicine.org, Feb. 24, 2010, 1… [cited by applicant]
Lecoeur, Nuclear Apoptosis Detection by Flow Cytometry: Influence of Endogenous Endonucleases, Experimental Cell Research, vol. 277, No. 1, Jul. 1, 2002, pp. 1-14. [cited by applicant]
Li et al., New Hope for Tumor Diagnosis—Detection of Circulating Free DNA, Chinese Journal of Clinical Pathologist, vol. 7, No. 2, Jun. 30, 2015, 14 pages. [cited by applicant]
Li et al., Size Separation of Circulatory DNA in Maternal Plasma Permits Ready Detection of Fetal DNA Polymorphisms, Clinical Chemistry, Molecular Diagnostics and Genetics, vol. 50, No. 6, Jun. 2004, pp. 1002-1011. [cited by applicant]
Liao et al., Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles, Clinical Chemistry, vol. 57, No. 1, Jan. 2011, pp. 92-101. [cited by applicant]
Lo et al., Digital PCR for the Molecular Detection of Fetal Chromosomal Aneuploidy, Proceedings of the National Academy of Sciences, vol. 104, No. 32, Aug. 7, 2007, pp. 13116-13121. [cited by applicant]
Lo et al., Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus, Science Translation Medicine, vol. 2, No. 61, Dec. 8, 2010, pp. 1-13. [cited by applicant]
Lo et al., Quantitative Analysis of Cell-free Epstein-Barr Virus DNA in Plasma of Patients with Nasopharyngeal Carcinoma, Cancer Research, vol. 59, Mar. 1999, pp. 1188-1191. [cited by applicant]
Longo, Tumor Heterogeneity and Personalized Medicine, The New England Journal of Medicine, vol. 366, No. 10, Available Online at: www.nejm.org, Mar. 8, 2012, pp. 956-957. [cited by applicant]
Lun et al., Noninvasive Prenatal Diagnosis of Monogenic Diseases by Digital Size Selection and Relative Mutation Dosage on DNA in Maternal Plasma, Proceedings of the National Academy of Sciences of the United States of … [cited by applicant]
McDermott et al., Genomics and the Continuum of Cancer Care, The New England Journal of Medicine, vol. 364, No. 4, Jan. 27, 2011, pp. 340-350. [cited by applicant]
Meyerson et al., Advances in Understanding Cancer Genomes Through Second-Generation Sequencing, Nature Reviews Genetics, vol. 11, No. 10, Oct. 2010, pp. 685-696. [cited by applicant]
Miller et al., Genome-Wide Molecular Characterization of Central Nervous System Primitive Neuroectodermal Tumor and Pineoblastoma, Neuro-Oncology, vol. 13, No. 8, Aug. 2011, pp. 866-879. [cited by applicant]
Mitchell et al., High Sensitivity and Specificity of Chromosomal Pertubations in Human Invasive Breast Cancer (BrCa) Associated with Circulating Nucleic Acids (CNA) Using Concatemers of Short Sequence DNA Tags in Next G… [cited by applicant]
Mouliere et al., High Fragmentation Characterizes Tumour-Derived Circulating DNA, PLOS One, vol. 6, No. 9, e23418, Sep. 6, 2011, pp. 1-10. [cited by applicant]
Muller et al., Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements, Clinical Chemistry, vol. 54, No. 4, Apr. 1, 2008, pp… [cited by applicant]
Murtaza et al., Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA, Nature, vol. 497, No. 7447, May 2, 2013, pp. 108-112. [cited by applicant]
Nannya et al., A Robust Algorithm for Copy Number Detection Using High-Density Oligonucleotide Single Nucleotide Polymorphism Genotyping Arrays, Cancer Research, vol. 65, No. 14, Jul. 15, 2005, pp. 6071-6079. [cited by applicant]
Palomaki et al., DNA Sequencing of Maternal Plasma to Detect Down Syndrome: An International Clinical Validation Study, Genetics in Medicine, vol. 13, No. 11, Nov. 2011, pp. 913-920. [cited by applicant]
International Application No. PCT/AU2011/001562, International Search Report and Written Opinion, mailed on Feb. 17, 2012, 8 pages. [cited by applicant]
International Application No. PCT/CN2016/073753, International Search Report and Written Opinion, mailed on May 10, 2016, 7 pages. [cited by applicant]
International Application No. PCT/CN2016/091531, International Preliminary Report on Patentability, mailed on Feb. 1, 2018, 5 pages. [cited by applicant]
International Application No. PCT/CN2016/091531, International Search Report and Written Opinion, mailed on Sep. 28, 2016, 11 pages. [cited by applicant]
International Application No. PCT/CN2018/074138, International Preliminary Report on Patentability, mailed on Jul. 30, 2019, 5 pages. [cited by applicant]
International Application No. PCT/CN2018/074138, International Search Report and Written Opinion, mailed on Apr. 28, 2018, 10 pages. [cited by applicant]
International Application No. PCT/CN2018/097072, International Preliminary Report on Patentability, mailed on Jan. 28, 2020, 4 pages. [cited by applicant]
International Application No. PCT/EP2010/066935, International Search Report and Written Opinion, mailed on Feb. 23, 2011, 10 pages. [cited by applicant]
International Application No. PCT/IB2013/000312, International Search Report and Written Opinion, mailed on Jun. 18, 2013, 13 pages. [cited by applicant]
International Application No. PCT/IB2013/054898, International Preliminary Report on Patentability, mailed on Dec. 31, 2014, 7 pages. [cited by applicant]
International Application No. PCT/IB2013/054898, International Search Report and Written Opinion, mailed on Dec. 23, 2013, 16 pages. [cited by applicant]
International Application No. PCT/US2010/055655, International Search Report and Written Opinion, mailed on Apr. 20, 2011, 20 pages. [cited by applicant]
International Application No. PCT/US2015/042310, International Search Report and Written Opinion, mailed on Jan. 12, 2016, 17 pages. [cited by applicant]
International Application No. PCT/US2017/058099, International Search Report and Written Opinion, mailed on Mar. 6, 2018, 20 pages. [cited by applicant]
Pennisi, Single-Cell Sequencing Tackles Basic and Biomedical Questions, Science, vol. 336, No. 6084, May 25, 2012, pp. 976-977. [cited by applicant]
Peter et al., Cell-Free DNA Fragmentation Patterns in Amniotic Fluid Identify Genetic Abnormalities and Changes Due to Storage, Diagnostic Molecular Pathology, vol. 17, No. 3, Sep. 2008, pp. 185-190. [cited by applicant]
Prokunina-Olsson et al., Cancer Sequencing Gets a Little More Personal, Available Online at: www.ScienceTranslationalMedicine.org, vol. 2, No. 20, Feb. 24, 2010, pp. 1-3. [cited by applicant]
Psifidi et al., Novel Quantitative Real-time LCR for the Sensitive Detection of SNP Frequencies in Pooled DNA: Method Development, Evaluation and Application, PLoS ONE, vol. 6, No. 1, e14560, Jan. 19, 2011, pp. 1-11. [cited by applicant]
Qin et al., Studying Copy Number Variations Using a Nanofluidic Platform, Nucleic Acids Research, vol. 36, No. 18, Oct. 2008, pp. 1-8. [cited by applicant]
Razavi et al., Many Cell-free DNA (CfDNA) Mutations are Derived from Clonal Hematopoiesis: Implications for Interpretation of Liquid Biopsy Tests, GRAIL-MSK WBC Poster, ASCO, vol. 35, No. 15, Available online at: https:… [cited by applicant]
Razavi et al., Performance of a High-Intensity 508-Gene Circulating-Tumor DNA (ctDNA) Assay in Patients With Metastatic Breast, Lung, and Prostate Cancer, GRAIL-MSK concordance Poster, ASCOM, vol. 35, No. 18, Available … [cited by applicant]
Reed et al., Non-Invasive Determination of the Paternal HLA Haplotype of a Fetus Using Kinetic PCR to Detect Fetal Microchimerism in Maternal Plasma, Bone Marrow Transplantation, vol. 29, No. 6, Mar. 2002, pp. 527-529. [cited by applicant]
Salani et al., Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant Versus Benign Effusions, Cancer Research, vol. 13, No. 19, Oct. 1, 2007, pp. 5805-5809. [cited by applicant]
Schwarzenbach et al., Cell-Free Nucleic Acids as Biomarkers in Cancer Patients, Nature Reviews Cancer, Advance Online Publication, vol. 11, No. 6, Jun. 2011, pp. 426-437. [cited by applicant]
Singapore Application No. 1201408113Q, Written Opinion, mailed on Aug. 16, 2017, 6 pages. [cited by applicant]
Singapore Application No. 11201408113Q, Written Opinion, mailed on Aug. 4, 2016, 7 pages. [cited by applicant]
Singapore Application No. 11201408113Q, Written Opinion, mailed on Dec. 8, 2015, 8 pages. [cited by applicant]
Singapore Application No. 11201706529T, Written Opinion, mailed on Jun. 19, 2018, 7 pages. [cited by applicant]
Shaw et al., Genomic Analysis of Circulating Cell-Free DNA Infers Breast Cancer Dormancy, Genome Research, vol. 22, No. 2, Feb. 2012, pp. 220-231. [cited by applicant]
Shoda et al., Clinical Utility of Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Gastric Cancer, Oncotarget, vol. 8, No. 17, Apr. 25, 2017, pp. 28796-28804. [cited by applicant]
Shotelersuk et al., Epstein-Barr Virus DNA in Serum/Plasma as a Tumor Marker for Nasopharyngeal Cancer, Clinical Cancer Research, vol. 6, Mar. 31, 2000, pp. 1046-1051. [cited by applicant]
Snyder et al., Cell-Free DNA Comprises an in Vivo Nucleosome Footprint that Informs its Tissues-of-Origin, Cell, vol. 164, Jan. 14, 2016, pp. 57-68. [cited by applicant]
Snyder et al., Noninvasive Fetal Genome Sequencing: A Primer, NIH Public Access Author Manuscript in PMC, vol. 33, No. 6, Jun. 2013, pp. 547-554. [cited by applicant]
Snyder et al., Universal Noninvasive Detection of Solid Organ Transplant Rejection, Proceedings of the National Academy of Sciences, vol. 108, No. 15, Apr. 12, 2011, pp. 6229-6234. [cited by applicant]
Stratton, Exploring the Genomes of Cancer Cells: Progress and Promise, Science, vol. 331, No. 6024, Mar. 25, 2011, pp. 1553-1558. [cited by applicant]
Stratton et al., The Cancer Genome, Nature, vol. 458, No. 7239, Apr. 9, 2009, pp. 719-724. [cited by applicant]
Straver et al., Calculating the Fetal Fraction for Noninvasive Prenatal Testing Based on Genome-Wide Nucleosome Profiles, Prenatal Diagnosis, vol. 36, 2016, pp. 614-621. [cited by applicant]
Su et al., Inferring Combined CNV/SNP Haplotypes from Genotype Data, Bioinformatics, vol. 26, No. 11, Jun. 1, 2010, pp. 1437-1445. [cited by applicant]
Sun et al., Research Progress of Circulating DNA and Clinical Tumor, Medical Recapitulate, vol. 16, No. 9, May 31, 2010, pp. 1348-1350. [cited by applicant]
Taback et al., Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients, Cancer Research, vol. 61, Aug. 1, 2001, pp. 5723-5726. [cited by applicant]
Tan et al., Evaluation of Plasma Epstein-Barr Virus DNA Load as a Prognostic Marker for Nasopharyngeal Carcinoma, Singapore Medical Journal, vol. 47, No. 9, Sep. 2006, pp. 803-807. [cited by applicant]
Tao et al., Rapid Growth of a Hepatocellular Carcinoma and the Driving Mutations Revealed by Cell-Population Genetic Analysis of Whole-Genome Data, Proceedings of the National Academy of Sciences of the United States of… [cited by applicant]
Thierry et al., Origin and Quantification of Circulating DNA in Mice with Human Colorectal Cancer Xenografts, Nucleic Acids Research, vol. 38, Issue 18, May 21, 2010, pp. 6159-6175. [cited by applicant]
Torchinsky et al., Sizing Femtogram Amounts of dsDNA by Single-Molecule Counting, Nucleic Acids Research, vol. 44, No. 2, e17, Sep. 13, 2015, 6 pages. [cited by applicant]
Tsang et al., Circulating Nucleic Acids in Plasma/Serum, Pathology, vol. 39, No. 2, Apr. 30, 2007, pp. 197-207. [cited by applicant]
Taiwan Application No. 102122036, Office Action, mailed on Feb. 8, 2017, 8 pages (4 pages of Original Document and 4 pages of English Translation). [cited by applicant]
Van Dijk et al., Library Preparation Methods for Next-Generation Sequencing: Tone Down the Bias, Experimental Cell Research, vol. 322, No. 1, Mar. 10, 2014, pp. 12-20. [cited by applicant]
Wagner, Free DNA—New Potential Analyte in Clinical Laboratory Diagnostics, Biochemia Medica, vol. 22, No. 1, Feb. 15, 2012, pp. 24-38. [cited by applicant]
Wang et al., Digital Karyotyping, Proceedings of the National Academy of Sciences U.S.A., vol. 99, No. 25, Dec. 10, 2002, pp. 16156-16161. [cited by applicant]
Weber et al., Detection of Human Tumor Cells by Amplicon Fusion Site Polymerase Chain Reaction (AFS-PCR), The Journal of Clinical Investigation, vol. 121, No. 2, Feb. 2011, pp. 545-553. [cited by applicant]
Welch et al., The Origin and Evolution of Mutations in Acute Myeloid Leukemia, Cell, vol. 150, No. 2, Jul. 20, 2012, pp. 264-278. [cited by applicant]
Xie et al., CNV-Seq, A New Method to Detect Copy Number Variation Using High-throughput Sequencing, BMC Bioinformatics, vol. 10, No. 80, Mar. 6, 2009, 9 pages. [cited by applicant]
Xu et al., Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor, Cell, vol. 148, No. 5, Mar. 2, 2012, pp. 886-895. [cited by applicant]
Yap et al., Intratumor Heterogeneity: Seeing the Wood for the Trees, Science Translational Medicine, vol. 4, No. 127, Available online at: www.sciencetranslationalmedicine.org, Mar. 28, 2012, pp. 1-4. [cited by applicant]
Yu et al., Size-Based Molecular Diagnostics Using Plasma DNA for Noninvasive Prenatal Testing, Proceedings of the National Academy of Sciences, vol. 111, No. 23, Jun. 10, 2014, pp. 8583-8588. [cited by applicant]
Yung et al., Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients, Clinical Cancer Research, vol. 15, No. 6, Mar. 15, 2009… [cited by applicant]
Zhao et al., Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis, Cancer Research, vol. 65, No. 13, Jul. 1, 2005, pp. 5561-5570. [cited by applicant]
Zheng et al., Nonhematopoietically Derived DNA is Shorter than Hematopoietically Derived DNA in Plasma: A Transplantation Model, Clinical Chemistry, vol. 58, No. 3, Mar. 2012, pp. 549-558. [cited by applicant]
U.S. Appl. No. 16/858,018, Notice of Allowance mailed on Jul. 1, 2022, 8 pages. [cited by applicant]
Ambinder et al., Using CpG Methylation to Monitor EBV in Plasma, Annals of Oncology, vol. 25, No. 5, Oct. 2014, p. v24. [cited by applicant]
Australian Application No. 2018305609, First Examination Report mailed on Jul. 11, 2022, 4 pages. [cited by applicant]
Japanese Application No. 2020-503956, Office Action mailed on Jun. 7, 2022, 10 pages (4 pages of Original Document and 6 pages of English Translation). [cited by applicant]
Malaysia Application No. PI2019002339, Substantive Examination Adverse Report mailed on Sep. 29, 2022, 3 pages. [cited by applicant]
Malaysia Application No. PI2019003873, Substantive Examination Adverse Report mailed on Mar. 22, 2022, 5 pages. [cited by applicant]
Singapore Application No. 11201906397U, Further Written Opinion mailed on Aug. 19, 2022, 7 pages. [cited by applicant]
Shamay et al., CpG Methylation as a Tool to Characterize Cell-free Epstein-Barr Virus DNA, Infectious Agents and Cancer, vol. 7, No. 1, Apr. 19, 2012, pp. 1-2. [cited by applicant]
Sun et al., Size-Tagged Preferred Ends in Maternal Plasma DNA Shed Light on the Production Mechanism and Show Utility in Noninvasive Prenatal Testing, Proceedings of the National Academy of Sciences, vol. 115, No. 22, M… [cited by applicant]
Taiwan Application No. 107102794, Office Action mailed on May 19, 2022, 10 pages (9 pages of Original Document and 1 pages of English Translation). [cited by applicant]
Taiwan Application No. 107125941, Office Action mailed on Jul. 15, 2022, 12 pages (7 pages of Original Document and 5 pages of English Translation). [cited by applicant]
Office Action dated Jul. 25, 2023 in IL Patent Application No. 272030. 4 pages. [cited by applicant]
Extended European Search Report dated Aug. 21, 2023 in EP Patent Application No. 23171661.4. 12 pages. [cited by applicant]
English translation of Office Action mailed Sep. 1, 2023 in CN Patent Application No. 201780080329.5. 11 pages. [cited by applicant]
Chinese Application No. 201780080329.5, Office Action mailed on Dec. 1, 2023, 18 pages. (8 pages of Original Document and 10 pages of English Translation). [cited by applicant]
Philippines Application No. 1-2020-500156, Office Action mailed on Nov. 7, 2023, 6 pages. (1 pages of Original Document and 1 pages of English Translation). [cited by applicant]
English translation of Office Action mailed Apr. 4, 2023 in JP Patent Application No. 2020-503956. 8 pages. [cited by applicant]
Mrozek-Gorska, Paulina et al.; “Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection”; PNAS; 2019; vol. 116, No. 32; https://www.pnas.org/doi/full/10.1073/pnas.1901314116; pp… [cited by applicant]
Examination Report No. 1 dated May 31, 2023 in AU Patent Application No. 2017347790. 4 pages. [cited by applicant]
Canadian Application No. 3,070,898, Office Action mailed on Feb. 29, 2024, 5 pages. [cited by applicant]
Clarke et al., Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer, Cancer Epidemiology, Biomarkers & Prevention, vol. 21, No. 12, Dec. 2012, pp. 2125-2137. [cited by applicant]
Ji et al., Evaluation of Plasma Epstein-Barr Virus DNA Load to Distinguish Nasopharyngeal Carcinoma Patients From Healthy High-Risk Populations in Southern China, Cancer, vol. 120, No. 9, May 1, 2014, pp. 1353-1360. [cited by applicant]
Kwok et al., From Conventional to Next Generation Sequencing of Epstein-Barr Virus Genomes, Viruses, vol. 8, No. 3, Feb. 24, 2016, pp. 1-15. [cited by applicant]
Malaysian Application No. PI2020000327, Substantive Examination Adverse Report mailed on Feb. 16, 2024, 4 pages. [cited by applicant]
English translation of Office Action and Search Report mailed Mar. 20, 2024 in TW Patent Application No. 112116081. 5 pages. [cited by applicant]
English translation of Office Action mailed Aug. 6, 2024 in JP Patent Application No. 2023-126899. 7 pages. [cited by applicant]
Office Action dated Oct. 9, 2024 in CA Patent Application No. 3,041,647. 5 pages. [cited by applicant]
Examination Report No. 1 dated Oct. 10, 2024 in AU Patent Application No. 2023202318. 4 pages. [cited by applicant]